Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Lucentis 10 mg/ml solution for injection in pre-filled syringe

Active Ingredient:
ATC code: 
S01LA04
{info_black}
About Medicine
Audio Guides to Lucentis - Click on the PLAY button to listen, or right click to save the audio file. To view or download a text version see the 'Risk Materials' tab.

Lucentis ( ranibizumab) - Patient Booklet (AMD) - Audio Version
This guide was created to help you better understand LUCENTIS® when used for the treatment of neovascular (wet) age-related macular degeneration (AMD)



Lucentis (ranibizumab) - Patient booklet (RVO) - Audio Version
This guide was created to help you better understand LUCENTIS® when used for the treatment of visual impairment due to retinal vein occlusion (RVO)



Lucentis (ranibizumab) - Patient booklet (CNV) - Audio Version
This guide was created to help you better understand LUCENTIS® when used for the treatment of visual impairment due to choroidal neovascularization (CNV).



Lucentis (ranibizumab) - Patient booklet (PDR/DMO)- Audio Version
This guide was created to help you better understand LUCENTIS® when used for the treatment of Diabetic macular oedema (DMO) and/or Proliferative diabetic retinopathy.



Novartis Pharmaceuticals UK Ltd
Company image
Address
2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ
Telephone
+44 (0)1276 692 255
Medical Information Direct Line
+44 (0)1276 698 370
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)845 741 9442